National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease.
about
Homocysteine lowering interventions for preventing cardiovascular eventsPrognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology studyBiomarkers of Nutrition for Development-Folate ReviewWhole food versus supplement: comparing the clinical evidence of tomato intake and lycopene supplementation on cardiovascular risk factorsCRP in cardiovascular diseaseSecondhand Smoke Exposure and Subclinical Cardiovascular Disease: The Multi-Ethnic Study of AtherosclerosisA Cross-Sectional Study of the Cardiovascular Effects of Welding FumesLipid-related markers and cardiovascular disease prediction.The protective effect of phaseolus vulgaris on cataract in type 2 diabetes: a profitable hypothesis.A-FABP concentration is more strongly associated with cardiometabolic risk factors and the occurrence of metabolic syndrome in premenopausal than in postmenopausal middle-aged womenSignificance of C-reactive protein in osteoarthritis and total knee arthroplasty outcomes.Update on the NCEP ATP-III emerging cardiometabolic risk factors.High-sensitive factor I and C-reactive protein based biomarkers for coronary artery diseaseConsolidated and emerging inflammatory markers in coronary artery diseaseMipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.Soy provides modest benefits on endothelial function without affecting inflammatory biomarkers in adults at cardiometabolic riskSix-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortalitySevere multivessel coronary artery disease and high-sensitive troponin T.Hierarchical modelling of blood lipids' profile and 10-year (2002-2012) all cause mortality and incidence of cardiovascular disease: the ATTICA study.Creating the Future of Evidence-Based Nutrition Recommendations: Case Studies from Lipid Research.Trends in laboratory test volumes for Medicare Part B reimbursements, 2000-2010C-reactive protein, fibrinogen, and cardiovascular disease prediction.C-reactive protein and B-type natriuretic peptide yield either a non-significant or a modest incremental value to traditional risk factors in predicting long-term overall mortality in older adults.C-reactive Protein Concentration Is Associated With a Higher Risk of Mortality in a Rural Korean Population.High sensitivity C-reactive protein distribution in the elderly: the Bambuí Cohort Study, Brazil.2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.From evidence to practice: consensus in cardiovascular risk assessment and diabetes.Nutritional Status in Adults with Predialysis Chronic Kidney Disease: KNOW-CKD Study.C-reactive protein: clinical and epidemiological perspectives.Body mass index and glycemic control influence lipoproteins in children with type 1 diabetesIntegrating biomarkers: the new frontier?Serum Cystatin C and the Risk of Coronary Heart Disease in Ethnic Chinese Patients With Normal Renal Function.Inflammation, high-sensitivity C-reactive protein, and vascular protection.The association between depressive symptoms and insulin resistance, inflammation and adiposity in men and women.ApoB/ApoA-I ratio is independently associated with carotid atherosclerosis in type 2 diabetes mellitus with well-controlled LDL cholesterol levels.
P2860
Q24239981-1DB565FD-9870-4C41-BBBC-3E6AA88AF0A2Q24289043-A351EAE3-E218-48B3-990D-36BBBBB0D466Q26785463-41B16677-4B69-4231-9EC0-EBF51C2C534AQ28253143-9AAA788D-AB33-42D8-B912-FAD6E04002D0Q28268282-8B6106E6-C30D-4558-A760-258E90570699Q28397665-947034DE-EC3E-4E7A-9180-A9237D4D002FQ28397849-332E1F5E-427B-4BE1-92A4-9B9F68B03E9AQ28654304-5ECC8797-B25A-403E-9633-D53808652B0DQ33597063-7ED6704D-877E-4A7F-9A3C-2408185576CBQ33757446-92098898-B55F-47FE-A123-A463A631CB0DQ34424962-C20A6DC2-2D2F-4E94-8B67-46A1F3D0BB7BQ34811590-DDE32FB1-214E-44AA-95BA-B462A264AAC4Q35017096-5A62368A-3165-4FFE-9619-A05DC620D9E7Q35019922-90A893A9-4A0E-4F12-8FF3-839A5676F93EQ35130714-AF7C9AAC-B45F-48BB-8F92-9DA7C1EEF5CAQ35671503-3CD126A5-B416-492F-AF22-1E6D82F81441Q35994613-CFEEEDD5-2498-488E-8C61-47A5FBED26D0Q35997173-25BFD505-C63E-4F81-8C87-4240CBCD2309Q36061533-D07B8A8B-5414-4A1A-B990-E7391D1F023FQ36079167-027032A5-15D3-4034-AD6E-F2DCAF9CACDFQ36423616-A0D5767B-F096-4DCF-B084-870B5C1C92E4Q37021409-D61D281C-BBB9-499B-95F0-45D97B32D916Q37273542-1F722C17-E822-49B5-96B6-DC6C26A8A352Q37343374-034B2CB5-08B2-4864-A599-536AA62C0FB3Q37371016-7F599C3C-DA04-40CB-AF59-6400195F8156Q37435149-9C2C59EA-8F85-4470-B095-341F8179AA29Q37470277-347F769C-FC94-4D9D-900B-4C0F7A0E8DDEQ37570183-503ABD18-11FC-481E-AB70-3A55D4136493Q37599325-2BE8833A-4FF8-4C1A-A22E-A193B25A0ED7Q37730345-FAB8DF66-913A-47DD-B281-0545449A6D69Q39867930-02239905-F661-42DC-BA61-3229B6B82DA6Q40998882-5A96DBDC-36BE-4511-B3D3-0A306E6CD160Q42905345-734C5BE3-B5A2-4948-B47F-8DBB23EC6ED5Q47159698-1F23956E-244C-4867-B9CD-234A75813F9EQ49223170-F2884960-A20C-4F0D-BFCE-86B2C9D738A0
P2860
National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease.
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
National Academy of Clinical B ...... ion of cardiovascular disease.
@ast
National Academy of Clinical B ...... ion of cardiovascular disease.
@en
National Academy of Clinical B ...... ion of cardiovascular disease.
@nl
type
label
National Academy of Clinical B ...... ion of cardiovascular disease.
@ast
National Academy of Clinical B ...... ion of cardiovascular disease.
@en
National Academy of Clinical B ...... ion of cardiovascular disease.
@nl
prefLabel
National Academy of Clinical B ...... ion of cardiovascular disease.
@ast
National Academy of Clinical B ...... ion of cardiovascular disease.
@en
National Academy of Clinical B ...... ion of cardiovascular disease.
@nl
P2093
P1433
P1476
National Academy of Clinical B ...... ion of cardiovascular disease.
@en
P2093
Christie M Ballantyne
Christine M Pfeiffer
Daniel Levy
Darwin R Labarthe
Gary L Myers
Gerald R Cooper
NACB LMPG Committee Members
Peter W F Wilson
Robert H M Christenson
Scott M Grundy
P304
P356
10.1373/CLINCHEM.2008.115899
P407
P577
2008-12-23T00:00:00Z